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SUMMARY 1 
Clostridium difficile is the main causative agent of antibiotic-associated and health care 2 
associated infective diarrhea. Recently, there has been growing interest in alternative 3 
sources of C. difficile, other than patients with Clostridium difficile infection (CDI) and the 4 
hospital environment. Notably, the role of C. difficile colonized patients as a possible source 5 
of transmission has received attention. In this review, we present a comprehensive 6 
overview of the current understanding of C. difficile colonization. Findings from gut 7 
microbiota studies yield more insights in determinants that are important for acquiring or 8 
resisting colonization and progression to CDI. When discussing the prevalence of C. difficile 9 
colonization among populations and its associated risk factors, colonized patients at 10 
admission to the hospital merit more attention as findings from the literature have pointed 11 
to their role both in health care associated transmission of C. difficile and a higher risk of 12 
progression to CDI once admitted. C. difficile colonization among patients at admission may 13 
have clinical implications, although further research is needed to identify if interventions are 14 
beneficial to prevent transmission or overcome progression to CDI. 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
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INTRODUCTION 24 
Clostridium difficile is a spore-forming, gram-positive rod causing Clostridium difficile 25 
infection (CDI), which may range from mild diarrhea to life-threatening pseudomembranous 26 
colitis. Clostridium difficile infection has been considered as a healthcare associated 27 
infection transmitted primarily from other symptomatic CDI patients. Recent studies, 28 
notably based on highly discriminatory techniques like whole genome sequencing, have 29 
emphasized that assumptions about the sources and transmission of C. difficile may not be 30 
correct (1-3). The realization that a large proportion of CDI cases are not due to transmission 31 
from other CDI cases has underlined the need to re-examine the many diverse potential 32 
sources of C. difficile, and to determine their contribution to the epidemiology of this 33 
disease. Paramount to our understanding is the issue of colonization of C. difficile, which is 34 
the subject of this review. 35 
 36 
DEFINITIONS 37 
Definition of C. difficile colonization 38 
The authors of this review define  “C. difficile colonization ?ĂƐƚŚĞĚĞƚĞĐƚŝŽŶŽĨƚŚĞŽƌŐĂŶŝƐŵ39 
in the absence of CDI symptoms and  “C. difficile ŝŶĨĞĐƚŝŽŶ ?ĂƐƚŚĞƉƌĞƐĞŶĐĞŽĨC. difficile 40 
toxin (ideally), or a toxigenic strain type, and clinical manifestations of CDI (Figure 1). Clinical 41 
presentations compatible with CDI include diarrhea (defined as Bristol stool chart type 5-7, 42 
plus a stool frequency of three stools in 24 or fewer consecutive hours, or more frequently 43 
than is normal for the individual), ileus (defined as signs of severely disturbed bowel 44 
function such as vomiting and absence of stool with radiological signs of bowel distention) 45 
and toxic megacolon (defined as radiological signs of distention of the colon, usually >10 cm 46 
diameter, and signs of a severe systemic inflammatory response) (4).  47 
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However, as a previous review highlighted, definitions for CDI used in the Infectious Disease 48 
Societies of America (IDSA) and European Society of Clinical Microbiology and Infectious 49 
Diseases (ESCMID) guidelines differ (5-7). IDSA guidelines accept a CDI diagnosis if C. difficile 50 
symptoms are identified in combination with either the presence of a toxigenic strain, free 51 
toxin in the stool or histopathological evidence of pseudomembranous colitis, whereas 52 
recent ESCMID guidelines require the additional exclusion of alternative etiologies for 53 
diarrhea. Differences in definitions for CDI may affect the proportion of patients regarded as 54 
asymptomatically or symptomatically colonized instead of having symptomatic CDI. 55 
Moreover, the criteria used to define asymptomatic carriage/colonization vary considerably 56 
among studies. Strict definitions of colonization have been described (8, 9), including 57 
classifying asymptomatic carriers as those testing positive for C. difficile toxins but no signs 58 
of CDI for 12 weeks pre- or post-specimen collection, based on a retrospective record 59 
review (2). Highly restrictive definitions are difficult to apply in practice, and therefore use 60 
of a simplified definition of multiple positive stools from multiple time points to determine 61 
colonization has been recommended (10). In contrast, other studies utilized the less strict 62 
definition of colonization as a single C. difficile positive stool and the absence of diarrhea 63 
(11-13). Clearly, this has implications for who is classified as C. difficile colonized and how 64 
asymptomatic cohorts are perceived as potential transmission sources. Donskey and 65 
colleagues demonstrated that a single C. difficile positive fecal sample could imply either 66 
colonization, transient carriage or even  ‘ƉĂƐƐ-ƚŚƌŽƵŐŚ ? (10). We thus indicate the 67 
importance of further delineation of asymptomatic carriage into transient and persistent 68 
colonization, as outlined in a transmission study by Curry et al. (2). Differentiating between 69 
repeat, persistent detection (carriage) and point detection (colonization) would enable a 70 
greater understanding of transmission events and the infection control practices necessary 71 
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to prevent CDI spread. However, at the moment longitudinal studies on this topic are 72 
lacking.  73 
 74 
Assessing asymptomatic colonization 75 
The rates of asymptomatic colonization vary considerably due to the different definitions of 76 
diarrhea and laboratory methodological differences.  77 
 78 
Standardization of the definition of diarrhea is essential, since McFarland et al. defined 79 
diarrhea ĂƐш ?ƵŶĨŽƌŵĞĚƐƚŽŽůƐĨŽƌĂƚůĞĂƐƚƚǁŽĐŽŶƐĞĐƵƚŝǀĞĚĂǇƐ (14), whilst others 80 
accepted the same number of loose stools, but over a single 24 hour period (12, 15). 81 
Therefore, the absence of diarrhea is not synonymous with lack of loose stools, potentially 82 
resulting in inconsistent designations of asymptomatic patients.     83 
Besides the disparate definitions for diarrhea, assays or methodologies to test for CDI or C. 84 
difficile colonization also vary and impact incidence rates of both conditions (13). (See Table 85 
1) Methods used for CDI diagnosis can sometimes also be used for diagnosing C. difficile 86 
colonization, but on the other hand, some methods used for routinely diagnosing CDI may 87 
falsely classify colonized patients with diarrhea (due to a non-C. difficile cause) as CDI 88 
patients. 89 
Despite its labor intensive and time consuming characteristics and susceptibility to toxin 90 
degradation in stool samples with incorrect storage, cell cytotoxicity neutralization assay 91 
(CCNA) is frequently considered as the gold standard for CDI due to its high specificity and 92 
direct detection of the main virulence factor (toxin) (16, 17). However, as CCNA detects C. 93 
difficile toxins and not the presence of the organism itself, its utility is limited in detecting C. 94 
difficile colonization. Nonetheless, in infants, a positive CCNA without clinical symptoms has 95 
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been used to consider these infants as C. difficile colonized (18), indicating the aberrant 96 
association between toxin presence and clinical symptoms in this age group. 97 
An alternative gold standard for CDI is toxigenic culture, which includes culture of the 98 
organism followed by detection of its in vitro toxin producing capacity by toxin enzyme 99 
immunoassay (Tox A/B EIA), CCNA or detection of the toxin genes by nucleic acid 100 
amplification test (NAAT). A major study by Planche et al. of greater than 12,000 fecal 101 
specimens highlighted no increase in mortality in patients harboring a toxigenic C. difficile 102 
strain without the presence of detectable toxin (19), suggesting that free toxin positivity 103 
reflects CDI, while toxigenic culture positivity encompasses some patients with colonization. 104 
Therefore, the use of toxigenic culture to diagnose CDI could lead to an over-diagnosis of 105 
CDI and hence an underestimation of C. difficile colonization. However, if the goal is 106 
detection of toxigenic C. difficile colonization in asymptomatic patients, toxigenic culture is a 107 
suitable option. 108 
As both gold standard methods for diagnosing CDI are time-consuming and laborious, rapid 109 
assays are more appealing for CDI testing in daily practice. When rapid assays are used to 110 
test for CDI, it is recommended to use them in an algorithm in order to optimize positive 111 
and negative predictive values. Concerning the relationship between free toxins and true 112 
disease as described above, the algorithm should include a Tox A/B EIA to test for free 113 
toxins in stool. However, in clinical practice, rapid assays and especially NAATs, are often 114 
used as stand-alone test instead of as part of an algorithm, and this may again lead to C. 115 
difficile colonization being erroneously classified as CDI. A study by Polage et al. 116 
demonstrated that 39.9% of NAAT positive specimens tested negative for toxin by cell 117 
cytotoxicity assay (20), showing how reliance on stand-alone NAAT could lead to over-118 
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diagnosis of CDI and consequently an underestimation of asymptomatic colonization, similar 119 
to the situation described above for TC.  120 
 121 
There are some specific limitations that have to be taken into account when assessing C. 122 
difficile colonizationIn C. difficile colonization, bacterial loads can be lower than in CDI. 123 
Direct culture of the organism is quite sensitive, although detection rates will differ as the 124 
sensitivity of the culture media varies. Nonetheless, culture-independent detection 125 
techniques, such as enzyme immunoassays, have lower sensitivity and specificity than 126 
culture methods. As stools with lower counts of C. difficile could be deemed falsely negative, 127 
these assays may lead to underestimation of the asymptomatic colonization rates, making 128 
them less suitable for detection of colonization. For example, glutamate dehydrogenase 129 
(GDH) screening is regarded as highly specific for detection of C. difficile in clinical 130 
specimens (7, 21); however, potential issues have been highlighted with the use of this 131 
methodology for reporting asymptomatic colonization (22). In a study by Miyajima et al., 132 
only one out of five positives determined by an enrichment culture method was positive by 133 
GDH assay (22), probably due to low levels of GDH antigen in non-diarrheal stools, below 134 
the lower limits of detection for this assay.  135 
 136 
As the above illustrates, the diagnosis of CDI should not be based on laboratory results 137 
alone, but should always be supported by clinical signs and symptoms suggestive of CDI (7, 138 
23). This is especially important when methodologies which cannot discern CDI from 139 
colonization (stand-alone NAAT, TC) are applied in routine CDI testing.  140 
Likewise, we suggest that an optimal diagnostic method for the determination of 141 
asymptomatic colonization should include a confirmation of the absence of clinical 142 
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symptoms (i.e. absence of diarrhea, ileus and toxic megacolon per the criteria described 143 
above), or the presence of an alternative explanation for these clinical symptoms. The 144 
laboratory methods should include (enrichment) stool culture and either toxigenic culture 145 
or PCR confirmation. This combination of sensitive techniques, although expensive, will yield 146 
more reliable data and support inter-study comparisons.  147 
 148 
MECHANISMS OF C. DIFFICILE COLONIZATION 149 
After having defined C. difficile colonization, a closer look at mechanisms that underlie C. 150 
difficile colonization is needed. Key factors in acquiring or resisting colonization (and 151 
subsequent infection) are the gut microbiota and the host immune response against C. 152 
difficile. 153 
 154 
Disruptions in microbiota 155 
The gut microbiota has a prominent role in the whole life cycle of C. difficile from 156 
germination and colonization to establishing symptomatic disease. Results from studies on 157 
the differences in microbial composition in patients with CDI, asymptomatic carriers and 158 
non-infected patients can elucidate which alterations determine either the susceptibility to 159 
colonization and/or disease development or colonization resistance (defined as the 160 
resistance to colonization by ingested bacteria or inhibition of overgrowth of resident 161 
bacteria normally present at low levels within the intestinal tract) (24, 25). The optimal 162 
method to study the impact of the microbiota in spore germination, colonization and toxin 163 
production by C. difficile would be to take luminal samples and biopsies to study both 164 
microbiota attached to the intestinal wall and present in the lumen, as C. difficile was 165 
actually found in biofilm-like structures in the mucus layer of the murine gut and in a human 166 
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CDI gut model (26, 27). Also, ideally samples should be examined from different locations 167 
along the intestine, because it was demonstrated that in mice, C. difficile spores did 168 
germinate and grow in ileal contents, while this was not possible in cecal contents unless 169 
the mice had been treated with specific antibiotics (28). Obtaining these samples in human 170 
subjects is not feasible, though ingestible remotely controlled capsules that are capable of 171 
taking samples from the small intestinal tract are in development. However, most human 172 
studies use easy-to-obtain fecal samples for analyzing the intestinal microbiota, although 173 
these may actually not optimally reflect the microbial composition in the more proximal 174 
intestine where bile acid induced germination of the ingested spores occurs (see below). 175 
 176 
Alterations in gut microbial composition that have been described for CDI patients include a 177 
lower species richness and lower microbial diversity compared with healthy controls (29-178 
31). Between samples from CDI patients, a greater heterogeneity was observed than 179 
between individual samples from healthy controls (31). At the phylum level, Bacteroidetes 180 
were less prevalent in CDI patients than in healthy controls, while there was an increase in 181 
Proteobacteria. Within the Firmicutes phylum, a decrease in the Clostridia, especially from 182 
the Ruminococcaceae and Lachnospiraceae families and butyrate-producing anaerobic 183 
bacteria from Clostridium clusters IV and XIVa was noted in CDI patients (31). In addition to 184 
these depletions, increases in the orders of the Enterobacteriales and Pseudomonales 185 
(Proteobacteria) and Lactobacillales (Firmicutes) were observed (30, 31). Also, in human 186 
fecal samples collected prior to onset of a first CDI episode, a decreased diversity, a 187 
decrease in the phylum Bacteroidetes and changes within the phylum Firmicutes (a decrease 188 
in Clostridiales Incertae Sedis XI and an increase in Enterococacceae from the order 189 
Lactobacillales) were observed in comparison to samples from hospitalized patients who did 190 
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not develop CDI (32). A reduction in the family Clostridiales Incertae Sedis XI in these 191 
samples was demonstrated to be independently associated with CDI development . 192 
Moreover, changes in microbial composition comparable to those found in CDI patients 193 
have been described for patients with nosocomial diarrhea who tested negative for 194 
C.difficile or its toxins. These changes included a comparable decrease in species richness 195 
and microbial diversity and again a decrease in butyrate producing bacteria from the 196 
Ruminococcaceaea and Lachnospiraceae families in comparison to healthy controls (30, 31, 197 
33). This may indicate that patients with nosocomial diarrhea not due to CDI are also 198 
susceptible to development of CDI once they are exposed to C. difficile spores. It also 199 
suggests that the CDI itself did not much alter the gut microbial composition (31). Among 200 
mice that were given clindamycin to render them susceptible to CDI development, luminal 201 
samples and biopsies generally confirm the findings in humans and demonstrate a 202 
decreased species richness (34). Mice without antibiotic pre-exposure, and therefore 203 
undisturbed microbiota, do not develop CDI symptoms after administration of C. difficile 204 
spores (34). Also, in mice with CDI a microbiota dominated by Proteobacteria was 205 
demonstrated, instead of a Firmicutes and Bacteroidetes dominated microbiota as found in 206 
healthy mice (34, 35). 207 
 208 
Alterations in gut microbial composition in C. difficile carriers are less well described, but 209 
may give more insight in the mechanisms that allow for colonization whilst protecting 210 
against the development of overt disease. One of the few available studies reports a 211 
decreased species richness and decreased microbial diversity not only in samples from 8 CDI 212 
patients but also in samples from 8 asymptomatic carriers, compared to 9 healthy subjects 213 
(29). However, the structure of the microbial community was significantly different among 214 
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CDI patients and carriers and therefore it is suggested that the absence or presence of 215 
certain bacterial taxa is more important in determining the development of CDI or C. difficile 216 
colonization than the diversity of species richness alone. In carriers, fewer Proteobacteria 217 
and a higher proportion of Firmicutes and Bacteroidetes were found than in CDI patients 218 
and so this distribution resembled that of healthy individuals more (29). Another study 219 
among 98 hospitalized patients (including 4 CDI patients and 4 C. difficile colonized patients) 220 
showed that, compared with CDI patients, a higher level of Clostridiales Family XI Incertae 221 
Sedis, Clostridium or Eubacterium was found just before C. difficile colonization was 222 
detected, also supporting the notion that the presence of certain bacterial taxa is important 223 
to prevent overgrowth or progression from colonization to overt infection (36). Evidence 224 
from murine studies also indicates that colonization with certain bacterial taxa may prevent 225 
the progression from colonization to CDI; mice precolonized with a murine Lachnospiracea 226 
isolate showed significantly reduced C. difficile colonization (37). Similarly, administration of 227 
Clostridium scindens in antibiotic-treated mice is associated with resistance to CDI (38). 228 
Moreover, in antibiotic-exposed mice who were challenged with C. difficile spores, different 229 
patterns in microbiota composition were seen in those that developed severe CDI 230 
symptoms versus animals who became only C. difficile colonized (35). In the first group, a 231 
shift towards Proteoabacteria was noted, while the latter group had a microbiota that was 232 
dominated by Firmicutes (including Lachnospiraceae) resembling that of mice who had not 233 
been exposed to antibiotics. The presence of a Firmicutes dominated microbiota seemed to 234 
be protective against the development of clinical symptoms in this experiment (35).  235 
Interestingly, a recent longitudinal study in a C. difficile colonized infant showed important 236 
changes in microbiota composition during weaning. An increase in the relative abundance of 237 
Bacteroides, Blautia, Parabacteroides, Coprococcus , Ruminococcus, and Oscillospira was 238 
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noted suggesting that these bacterial genera likely account for the expulsion of C. difficile 239 
(39). 240 
 241 
In conclusion, there are only a few studies on the intestinal microbiota in patients with 242 
asymptomatic C. difficile colonization, which are also very limited in sample sizes. However, 243 
these studies and findings from mice studies support the idea that a decreased species 244 
richness and decreased microbial diversity appear to allow for colonization, although the 245 
presence of certain bacterial taxa seems to protect from progression to CDI. Mechanisms by 246 
which the microbiome and in particular the presence of certain bacterial taxa may offer 247 
colonization resistance and protection against infection will be described below. 248 
 249 
The role of the microbiota: bile acid metabolism 250 
The first step in establishing C. difficile colonization is the germination of spores. Primary 251 
bile acids are known to stimulate this germination process (40). The physiological function 252 
of primary bile acids is to assist in digesting fat. To be able to do so, after being produced in 253 
the liver, primary bile acids are released into and reabsorbed from the small intestine. 254 
However, a small amount of the primary bile acids is not reabsorbed and is passed into the 255 
colon. In the colon, these primary bile acids are metabolized into secondary bile acids by 256 
certain members of the normal gut microbiota. Secondary bile acids inhibit C. difficile 257 
growth (40). The capacity to metabolize primary bile acids into secondary bile acids by the 258 
ƉƌŽĚƵĐƚŝŽŶŽĨďŝůĞĂĐŝĚ ?ɲ-dehydroxylating enzymes is shown in members of the 259 
Lachnospiraceae, Ruminococcaceae and Blautia families, all belonging to the phylum 260 
Firmicutes (28, 41). A disruption in the intestinal microbiota and depletion of Firmicutes may 261 
therefore cause an increase in primary bile acids and a decrease in secondary bile acids. This 262 
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was shown in antibiotic-treated mice, where loss of members of the Lachnospiraceae and 263 
Ruminococcaceae families was found to be correlated to a significant loss of secondary bile 264 
acids (28). More specifically, this was also shown for one of the members of the 265 
Lachnospiraceae family, C. scindens; the administration of this bacterium was shown to 266 
restore physiological levels of secondary bile acid synthesis (38). Loss of secondary bile acids 267 
and an increase in primary bile acids creates a favorable environment for C. difficile. Support 268 
for the role of bile acid metabolism in this susceptibility to C. difficile colonization is 269 
obtained from both in vitro and in vivo studies. In vitro, spores are able to germinate in the 270 
presence of bile acids concentrations found in feces of CDI patients; however, spore 271 
germination and vegetative growth was inhibited in the presence of bile acids at 272 
concentrations found in patients after fecal microbiota transplant (FMT) or in mice resistant 273 
to C. difficile (28, 42). In vivo significantly higher levels of primary bile acids and lower levels 274 
of secondary bile acids were found in feces from CDI patients compared with controls, 275 
especially in patients with a recurrent CDI episode (43). Notably, the amount of germination 276 
in response to bile acids seems to vary between strains, which may be related to mutations 277 
in the CspC germinant receptor (called CspC) that recognizes the primary bile acids (42). A C. 278 
difficile mutant completely deficient for the CspC receptor gene was demonstrated to cause 279 
less severe clinical symptoms in a hamster model (40). 280 
 281 
The role of the microbiota: other mechanisms 282 
Apart from the altered bile acid composition, other mechanisms also induced by disruptions 283 
of the microbiota are suggested to play a role in conferring susceptibility to C. difficile. 284 
First, disruptions in the microbiota that lead to a diminished production of short chain fatty 285 
acids (SCFAs) may be of importance. SCFAs are produced from dietary and host-derived 286 
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carbohydrates mainly by Lachnospiraceae and Ruminococcaceae, the families that were less 287 
abundant in CDI patients and carriers. They may have effect on colonization resistance 288 
through reducing the luminal pH (and thereby creating an unfavorable environment for C. 289 
difficile) (44) and stimulating the defense barrier as one of the SCFAs (butyrate) is the main 290 
energy source of the gut epithelium (45, 46). Amino acids may also play a role in the 291 
susceptibility to C. difficile colonization, as they can enhance germination in the presence of 292 
secondary bile acids and may influence the immune system. Moreover, the digestion of 293 
carbohydrates in the gut results may impact susceptibility for CDI development. 294 
Bacteroidetes are mainly responsible for this carbohydrate digestion which results in 295 
production of substrates essential for homeostasis of colonocytes (47). A reduction in 296 
Bacteroidetes may therefore negatively impact colonic health. 297 
Besides the indirect mechanisms described above, the microbiota may also have direct 298 
resistant mechanisms against C. difficile. These include competition for niches and nutrients 299 
and the production of antimicrobials (48, 49). 300 
 301 
The role of the immune system: innate immunity 302 
The precise protective factors of the innate immunity that prevent colonization and 303 
progression to CDI are unknown, but are probably less important than the role of the 304 
microbiota and bile acid metabolism. Virulence factors of C. difficile induce a rapid innate 305 
immune response resulting in an inflammatory response which is necessary to induce 306 
adaptive immunity.  307 
CDI is characterized by a severe intestinal inflammatory response in which neutrophils 308 
infiltrate the mucosa. TcdA and TcdB play an important role in eliciting this inflammatory 309 
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response (50). After epithelial barrier disruption, TcdA and TcdB trigger inflammatory 310 
signaling cascades through activation of NF-kB, AP-1 and inflammasome, and stimulate 311 
production of pro-inflammatory cytokines and chemokines in epithelial cells. This promotes 312 
the recruitment of immune cells including neutrophils and induces the production of 313 
defensins. Surface proteins also trigger an innate immune response. Challenge of 314 
macrophages with C. difficile surface proteins (surface layer proteins, SLPs) leads to pro-315 
inflammatory cytokine production such as TNF-ɲ ?/>- ?ɴĂŶĚ/>-8 (51). 316 
Additionally, C. difficile SLPs interact in vitro with TLR4 leading to dendritic cell (DC) 317 
maturation, robust Th1 and Th17 responses with production of IFNJ and IL-17, and a weak 318 
Th2 response leading to antibody production (52). Ryan et al. showed that TLR4 and myeloid 319 
differentiation primary-response protein 88 (MyD88) deficient mice were more prone to C. 320 
difficile infection (53). C. difficile flagellin FliC also activates an innate immune response via 321 
its interaction with TLR5 inducing predominantly activation of p38 MAPK and, to a lesser 322 
extent NF-NB, resulting in up-regulation of the expression of pro-inflammatory cytokine 323 
genes and the production of pro-inflammatory factors (54, 55). In vivo, Batah et al. showed 324 
a synergic effect of C. difficile flagellin and toxins in inducing mucosal inflammation (56).  325 
In summary, the innate immune response induces an inflammatory response which 326 
promotes an adaptive immune response with memory and long-lasting immunity (see 327 
below), but its effects on C. difficile colonization are unknown. 328 
 329 
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The role of the immune system: adaptive immunity 330 
The adaptive immunity against colonization or CDI has mainly been studied for its antibody-331 
mediated response whereas the role of the cell-mediated immune response remains 332 
unknown.   333 
Serum antibodies against somatic antigens and surface components have been found in 334 
asymptomatic carriers and patients recovered from CDI (57, 58), which suggests that surface 335 
proteins induce an immune response and modulate disease outcome. Vaccination assays 336 
with these proteins have been performed in animal models. Parenteral or mucosal 337 
vaccination with the S-layer proteins led to specific antibody production but only partial 338 
protection in the hamster model (59, 60). Immunization studies that were performed in 339 
animals with Cwp84 and the flagellar proteins FLIC and FliD by mucosal route resulted in a 340 
significant decrease in intestinal C. difficile colonization in the mouse model and partial 341 
protection in the hamster model (61, 62). Likewise, Ghose et al. immunized mice and 342 
hamsters intra-peritoneally with FliC adjuvanted with alum, inducing a high circulating anti-343 
FliC IgG response in animal sera, full protection in mice against a clinical 072/NAP1 strain, 344 
but only partial protection in hamsters against 63 ?ȴĞƌŵƐƚƌĂŝŶ(63). All these results suggest 345 
that antibodies against C. difficile surface proteins have a protective role against 346 
colonization. At the moment, studies with surface protein-based vaccines to prevent 347 
colonization in humans are lacking.  348 
Antibodies to TcdA and TcdB do not protect from colonization, but influence disease 349 
susceptibility and subsequently the progression from colonization into CDI. Kyne et al. 350 
studied anti-TcdA IgG antibody levels in patients who became colonized after C. difficile 351 
exposure. They found that patients who remained asymptomatically colonized had greater 352 
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increases in anti-TcdA IgG antibodies than patients who progressed from colonization to CDI 353 
(64).  354 
Monoclonal antibody (Mab)-based passive immunotherapy directed to toxins was able to 355 
protect hamsters from CDI. In humans, two Mabs, one targeting TcdA (actoxumab) and 356 
another targeting TcdB (bezlotuxumab) were tested in human clinical trials aimed at the 357 
prevention of recurrent disease (65). Bezlotoxumab prevented approximately 40% of the 358 
recurrences. A recently published hypothesis suggested that this reduction in recurrences is 359 
presumably due to limiting epithelial damage and facilitating rapid microbiome recovery 360 
(66), suggesting that reduced (re)colonization may be an important factor, although this 361 
should be explored further. Currently, two pharmaceutical firms (Pfizer and Valneva) have 362 
vaccine clinical trial development programmes with the two toxins (toxoids or toxin 363 
fragments) but no colonization factors as antigens (67); Sanofi Pasteur has recently 364 
announced the cessation of its vaccine development programme, which was also based on 365 
toxin antigens alone. Therefore these vaccines protect against the toxic effects of C. difficile 366 
on the intestinal mucosa, and can thereby hinder the progression from colonization to CDI.  367 
 368 
In conclusion, a rapid innate immune response induces adaptive immunity to CDI, of which 369 
the antibody-mediated response is best understood. Antibodies against C. difficile surface 370 
proteins are thought to protect against colonization, while antibodies against C. difficile 371 
toxins protect against disease, directly by its toxin neutralizing effect and possibly also 372 
indirectly by limiting epithelial damage and restoring colonization resistance.  373 
 374 
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SOURCES OF C. DIFFICILE - HUMAN 375 
Patients with CDI can shed C. difficile not only during the diarrheal episode, but also after 376 
completion of therapy. In a study of 52 patients receiving CDI treatment, samples from 377 
stool, skin and environmental sites were cultured for C. difficile before treatment, every 2-3 378 
days during treatment and weekly after therapy was completed (68). Prior to treatment, 379 
100% of stool samples and approximately 90% of skin and environmental samples were 380 
culture positive for C. difficile. Stool cultures became C. difficile negative in most patients by 381 
the time diarrhea resolved at a mean 4.2 days. However, at the same time, skin and 382 
environmental contamination with C. difficile remained high at 60% and 37% respectively. In 383 
addition, stool detection of C. difficile was 56% at 1-4 weeks post treatment among 384 
asymptomatic patients recovering from CDI. Moreover, 58% had skin contamination with C. 385 
difficile 1-4 weeks after completion of treatment and 50% had sustained environmental 386 
shedding. Persistent skin and environmental contamination was associated with receipt of 387 
additional antibiotic therapy. Prior to treatment, the mean density of C. difficile in stool 388 
samples was significantly higher than at the time that the diarrhea resolved, at end of 389 
treatment and at 1-6 weeks post treatment. This study highlights that patients with CDI can 390 
be a source of C. difficile spores and that they can potentially transmit C. difficile to other 391 
patients even after diarrhea has resolved. In addition, similar to animal models, continued 392 
antibiotic treatment can trigger Ă “ƐƵƉĞƌƐŚĞĚĚĞƌ ?ƐƚĂƚĞŝŶpatients, in which there is C. 393 
difficile overgrowth and excretion of high concentrations of spores (69).   394 
 395 
CDI was historically regarded as a healthcare associated infection transmitted primarily 396 
(directly or indirectly) by symptomatic patients, but a growing body of evidence 397 
demonstrates that asymptomatic carriers can also transmit the disease. 398 
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One study, using MLST (Multi Locus Sequence Typing) could link only 25% of patients with 399 
symptomatic CDI to a previously identified CDI patient (1). A follow-up study of the same 400 
large patient cohort (>1200 cases) used whole genome sequencing and was able to link at 401 
most only 55% (and more likely only 35%) of new cases to previous patients with CDI (3). A 402 
much smaller study (~50 cases) using MLVA (Multiple-Locus Variable number tandem repeat 403 
Analysis) found that only 30% of new cases could be linked to previously identified cases (2). 404 
One could argue that the inability to link new cases to previous ones might be caused by 405 
patients with CDI who are clinically undetected. However, strict criteria were used to 406 
determine which samples should be tested for CDI in the large UK study (1, 3); although a 407 
toxin EIA was used, which is not as sensitive as a reference test, repeat sampling was carried 408 
out according to clinical suspicion of CDI. Depending on the reference test used, the 409 
sensitivity of toxin EIA is approximately 60-85%, which means that 15-40% of patients with 410 
CDI may go undetected. Nonetheless, this does not account completely for the 45 to 75% of 411 
cases that were not closely linked to symptomatic patients (1, 3). This raises the question of 412 
what is/are the source(s) accounting for approximately half of new CDI cases? Curry et al. 413 
examined patients for C. difficile carriage who were selected to undergo screening for 414 
vancomycin-resistant enterococci. They found that 29% of CDIs could be linked to 415 
asymptomatic C. difficile carriers (2). 416 
 417 
As asymptomatic carriers and the associated shedding of spores usually goes undetected 418 
because of lack of routine screening, they can play a role in spread of C. difficile to the 419 
environment and other patients. Although transmission events from one individual 420 
asymptomatic carrier may be rare, as was shown in a relatively small study (15), 421 
asymptomatic carriers may still importantly contribute to the transmission of the disease as 422 
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they likely outnumber symptomatic CDI patients. A recent study showed that 2.6% of 423 
patients who were not exposed to C. difficile colonized patients developed CDI, while this 424 
percentage increased to 4.6% in patients who were exposed (70). Unfortunately, however, 425 
the case definition of CDI in this study was based on detection of toxin gene rather than 426 
toxin, and so over-diagnosis of true cases likely occurred. Asymptomatic carriers who are 427 
colonized at admission appear to contribute to sustaining transmission in the ward. Already 428 
in 1992, it was recognized that C. difficile strains introduced to the ward by asymptomatic 429 
carriers were important sources of onwards health care associated transmission (71), 430 
although definitive proof of linkage was hampered by use a non-specific typing technique. 431 
More recently, using an epidemiological model of C. difficile transmission in healthcare 432 
settings, Lanzas et al. confirmed that patients colonized on admission likely play a significant 433 
role in sustaining ward based transmission (72).  434 
 435 
ANIMAL AND ENVIRONMENTAL SOURCES OF C. DIFFICILE 436 
Animals 437 
Similar to humans, CDI or asymptomatic carriage can occur among domestic, farm and wild 438 
animals (73-80). Carriage rates in these studies range from 0-100%. These varied observed 439 
rates may be related to different culture methodologies and different study settings. Much 440 
of this subject has been reviewed in this journal but new information has emerged on 441 
possible transmission from domestic and farm animals (81, 82). 442 
 443 
C. difficile can cause diarrhea in domestic companion animals such as dogs and cats, but 444 
asymptomatic transient carriage of C. difficile by household pets is common (11-40%) (73, 445 
78, 83, 84). However, many of these studies did not analyze isolates from humans and pets 446 
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within the same household. A recent study examined the potential for transmission to pets 447 
from 8 patients with recurrent CDI (85), but in this study C. difficile was not found in any of 448 
the pets. In contrast, Loo et al. studied 51 families with 15 domestic pets that included 9 449 
cats, 5 dogs and 1 bird (86). During follow-up visits, toxigenic C. difficile was found in 450 
cultures of 2 cats and 2 dogs. Probable transmission occurred in 3 of the 15 domestic pet 451 
contacts. None of the domestic pets had diarrhea. Typing by pulsed-field gel electrophoresis 452 
showed that the profiles of all 4 domestic pet isolates were indistinguishable or closely 453 
related to those of their respective index patients. It is conceivable that household pets can 454 
serve as a potential source of C. difficile for humans.  455 
 456 
Transmission from farm animals to humans has been examined using whole genome 457 
sequencing using 40 Australian ribotype 014/NAP4 isolates of human and porcine origin 458 
(87). A clonal relationship with one or more porcine strains was demonstrated among 42% 459 
of human strains underscoring potential interspecies transmission. Similar findings were 460 
obtained in a study on 65 C. difficile 078/NAP7 isolates collected between 2002 and 2011 461 
that included 12 pairs of human and pig isolates from 12 different pig farms (88). Five 462 
(41.7%) of the 12 farmer-pig pairs were colonized with identical and nearly identical C. 463 
difficile clones (88); the remaining 7 (58.3%) farmer-pig pairs were not clonal suggesting 464 
exposure to different sources such as the environment. 465 
 466 
Food 467 
With reports that C. difficile can be detected among farm animals, studies of C. difficile 468 
detection in retail food products appeared.  469 
 470 
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Studies from Canada and the United States report that C. difficile can be recovered from 471 
retail meat including ground beef, ready to eat beef, ground pork, ground turkey, pork 472 
sausage, summer sausage, pork chorizo and pork braunschweiger, with prevalences ranging 473 
from 20-63% (89-92). 474 
 However, the prevalence of C. difficile in retail meat products was lower in European 475 
countries, ranging from 0-6.3% (93-95). The observed differences in prevalence of C. difficile 476 
culture positivity in retail meats in North American and Europe is striking. This may be 477 
related to seasonal and temporal changes, or may be true observed geographical 478 
differences. 479 
 480 
Using both quantitative and enrichment culture, Weese et al. sought to provide a measure 481 
of the degree of contamination from 230 samples of retail ground beef and pork (96). C. 482 
difficile was isolated from 28 (12%) and notably, approximately 70% of samples were 483 
positive by enrichment culture only. Among the samples that were positive on direct 484 
culture, the concentration of spores ranged from 20 to 240 spores/gram. Although the 485 
infectious dose of C. difficile is not known, these findings suggest that although C. difficile 486 
can readily be recovered from retail meat products, the concentration of C. difficile spores is 487 
low. 488 
 489 
Stabler et al. investigated the MLST profiles of 385 C. difficile isolates from human, animal 490 
and food sources and from geographically diverse regions (97). Animal and food strains 491 
were associated with the ST-1 and ST-11 profiles and these strains have been associated 492 
with CDI outbreaks in humans. Although the majority of C. difficile isolates recovered from 493 
retail food products are toxigenic and are of the same ribotypes or MLST to those of human 494 
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isolates, there have not been any human CDI cases that have been confirmed to be 495 
foodborne in origin.   496 
 497 
Environment 498 
C. difficile spores can survive in the environment for months or years due to their resistance 499 
to heat, drying, and certain disinfectants. Within hospitals, the surface environment is 500 
frequently contaminated with C. difficile. C. difficile has been cultured from many surfaces 501 
including floors, commodes, toilets, bed pans and high-touch surfaces such as call bells and 502 
overbed tables (14, 98). The frequency of environmental contamination depends on the C. 503 
difficile status of the patient: fewer than 8% of rooms of culture-negative patients, 8-30% of 504 
rooms of patients with asymptomatic colonization and 9-50% of rooms of CDI patients were 505 
found to be contaminated with C. difficile, respectively (14, 99, 100). 506 
 507 
To examine environmental sources outside of the healthcare milieu, Al Saif and Brazier 508 
undertook a large study of 2580 samples in Cardiff, South Wales from various sources 509 
including water, domestic and farm animals, soil, raw vegetables, surface samples from 510 
healthcare facilities, veterinary clinics and private residents (101). One hundred and eighty-511 
four (7.1%) samples were positive. Water samples gave the highest yield of culture positivity 512 
at 36%, followed by soil at 21% and healthcare environments at 20%. C. difficile was found 513 
in 59% of lawn samples collected in public spaces in Perth, Australia and toxigenic ribotypes 514 
014/NAP4 and 020/NAP4 were predominant (102). A Canadian study demonstrated that C. 515 
difficile was found in 39% of sediments sampled from rivers connected to the discharge 516 
effluent pipe of waste water treatment plants (103). The most common PCR ribotype was 517 
078/NAP7. 518 
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 519 
In summary, C. difficile has been isolated from animals, retail food and the environment. 520 
Using ribotyping and whole genome sequencing techniques, there appears to be 521 
interspecies and environmental transmission but the directionality of the transmission 522 
remains to be elucidated.  523 
 524 
EPIDEMIOLOGY OF ASYMPTOMATIC COLONIZATION  525 
After having discussed possible sources of C. difficile and underlying mechanisms of 526 
colonization, a description of the epidemiology of colonization, including the prevalence of 527 
colonization rates among different populations, is essential.  528 
 529 
Infants (0-24 months) 530 
Asymptomatic colonization rates in neonates and infants (<2 years) are widely reported as 531 
high, but range between 4-71% (18, 104-108). Although the clinical relevance of C. difficile 532 
colonization in infants is considered as less significant, due to low rates of disease in this 533 
population (109), its potential as a transmission reservoir for adult populations remains.  534 
 535 
An early study researching the prevalence of C. difficile in the neonate population found 536 
that approximately 30% of all newborns were asymptomatically colonized within their first 537 
month of life (18). However, these data included four specimens deemed positive with no 538 
identifiable organism, only toxin. Nonetheless, the transient nature of colonization at this 539 
early stage was highlighted with only 4 of 10 babies who were culture positive in the first 540 
week of life remaining positive at 14 and 28 days. A more recent review corroborated these 541 
early figures, pooling data from 5887 subjects to determine a colonization rate of 542 
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approximately 35% of infants under one year of age (105). This large-scale analysis suggests 543 
that colonization peaks between 6-12 months, before substantially decreasing towards 544 
adult rates. Although this major review provides a valuable assemblage of data, the 545 
variability across methodologies used by the included studies should be taken into 546 
consideration. 547 
 548 
Geographical differences in infant colonization rates have been identified, with one study 549 
indicating a variance of 4-35% across Estonian and Swedish infant populations respectively 550 
(108). The colonization rate was inversely associated with an elevated presence of inhibitory 551 
Lactobacilli in Estonian subjects, which may be determined by variation in diet and 552 
environmental exposure. A US study of hospitalized infants demonstrated a 20% 553 
colonization rate (110) whereas Furuichi et al. found no evidence of C. difficile colonization 554 
amongst Japanese newborns (111). However, the Japanese data were based on culture only, 555 
with no attempt to utilize EIA or NAAT to detect low levels of organism. These studies 556 
emphasize the variable epidemiology amongst diverse geographical populations.  557 
 558 
The source of infant colonization is uncertain, with suggestions that the presence of C. 559 
difficile in the urogenital tract implicated vaginal delivery as a potential route of 560 
transmission to neonates (112). However, later work contradicted this suggestion, failing to 561 
detect any C. difficile positive vaginal swabs from post-partum mothers (18, 104). Molecular 562 
analysis of both infant and environmental isolates demonstrate likely acquisition from 563 
environmental sources and patient to patient transmission (113). 564 
 565 
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Infants are rarely diagnosed with CDI. Bolton and colleagues found that almost 50% carried 566 
toxin positive strains, but showed no sign of diarrhea, suggesting that although the relevant 567 
toxin genes may be present, they may be minimally (or not) expressed and so fail to cause 568 
disease; alternatively, absent or immature toxin receptors may explain the infrequency of 569 
CDI despite high colonization rates (18). However, understanding toxigenic strain 570 
colonization rates may provide a greater insight into the relevance of this population as a 571 
reservoir for transmission to adults. Isolates from infants have shown predominance of 572 
ribotypes associated with CDI (106). Adlerberth et al. found that 71% of colonized infants 573 
had toxigenic strains with more than half identified as ribotypes 001/NAP2 and 014/NAP4 574 
that can cause endemic CDI (114). A comparison of C. difficile strains in children (<30 575 
months) with those circulating in the adƵůƚ ?ш ? ?ǇĞĂƌƐ ?/ƉŽƉƵůĂƚŝŽŶǁŝƚŚŝŶƚŚĞƐĂŵĞ576 
institution, determined nine shared sequence types among the 20% asymptomatic pediatric 577 
subjects (115). This may further implicate infants as a potential reservoir for C. difficile 578 
dissemination; nonetheless, no direct transmission events were documented in this limited 579 
pilot study. Potential community-based transmission from infant carriers to the adult 580 
population was alluded to in a longitudinal study demonstrating colonization in all 10 infants 581 
at some point in the first year of life, with 3 infants colonized for 4-9 months (116).   582 
 583 
Children (2-16 years) 584 
Meta-analysis of studies examining pediatric C. difficile epidemiology reported 585 
asymptomatic colonization in children older than 1 year at 15%, with prevalence reducing to 586 
5% in those greater than 2 years of age (117). One explanation for the reduction in 587 
colonization rates after infancy is that by 12 months the distribution of gut flora begins to 588 
closely resemble that of a healthy adult, providing a colonization resistance effect. 589 
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Nonetheless, contemporaneous studies have reported higher rates of up to 30% 590 
asymptomatic colonization amongst non-infant pediatric populations (111, 118, 119). 591 
Similarly, Merino and colleagues found that around a quarter of US children aged 1-5 years 592 
were colonized by C. difficile asymptomatically (120). By using a molecular identification 593 
method, classifying groups by the presence of the Toxin A gene (tcdA), the Toxin B gene 594 
(tcdB) and binary toxin genes (cdtA/B), they found that although 3/37 asymptomatically 595 
colonized children harbored a strain with toxigenic genes tcdA & tcdB, none carried the 596 
binary toxin genes cdtA/cdtB. Ferreira et al. (121) found low levels of toxigenic C. difficile in 597 
Brazilian children, arguing that the majority of acute diarrhea in this cohort is likely to be 598 
associated with entirely different enteropathogens. These epidemiological variations should 599 
be considered in the context of widely differing enteric pathogen populations between 600 
developing and developed countries. 601 
 602 
Healthy adults 603 
Previous studies indicate that the asymptomatic colonization rates amongst healthy 604 
individuals range from 4-15% (Figure 2). However, these studies have often been based on 605 
point prevalence detection of C. difficile, making a true carriage rate difficult to ascertain. 606 
Nevertheless, such a prevalence of even transient colonization by C. difficile suggests 607 
significant potential for exposure to the bacterium in the community setting among healthy 608 
populations.  609 
 610 
It is important to note the proportions of toxigenic strains because of their importance for 611 
transmission and potential for CDI. Work carried out amongst healthy Japanese adults 612 
reported a high colonization rate (15.4%), with around 70% harboring toxigenic strains 613 
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(122). However, a more recent US study discovered that all strains contributing to a 6.6% 614 
asymptomatic colonization rate were toxigenic (13). This rate is higher than seen in large 615 
patient transmission studies (2, 12, 71) suggesting that the healthy adult data may be 616 
skewed by relatively small study cohorts (n=149 (122); and n=139 (123)).  617 
 618 
Ozaki et al. identified matching PCR ribotypes amongst a cohort of healthy company 619 
employees, as a potential indication of a shared work place as a common source or 620 
representing human cross-transmission within this cohort (123). As well, they highlighted 621 
the transient nature of colonization, with only 37.5% demonstrating carriage with the same 622 
strain within a follow-up period of 1 year. Galdys et al. also found that approximately 33% of 623 
participants remained positive with the same strain, in samples submitted one month apart 624 
(13). Another study used cluster analysis to highlight that although colonization amongst 625 
healthy groups acts as a reservoir for community acquired CDI, it may only occur 626 
infrequently between families (124). Although a previous study has implicated the family 627 
environment as a source of transmission of C. difficile (125), Kato et al. found only one 628 
instance of a shared strain type amongst family members, across 22 families with 1 C. 629 
difficile colonized index patient.  630 
 631 
Patients at admission to a hospital 632 
Patients at admission to a hospital are a considerable reservoir for C. difficile and, 633 
importantly, a potential source of nosocomial transmission. Asymptomatic colonization 634 
rates among patients at admission to a hospital range from 3-21% (11, 12, 98, 126-132). 635 
(Figure 2) A large study by Clabots and colleagues reported that 9.6% of admissions to the 636 
study ward were colonized; admissions from home had the lowest colonization rate (6%), 637 
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but nonetheless accounted for the second most prevalent method of C. difficile 638 
introduction, due to their greater numbers (71). A major Canadian study of over 5000 639 
admissions demonstrated a lower C. difficile prevalence rate, with 4.05% asymptomatically 640 
colonized (133); this rate was very similar in a more recent large-scale study (4.8%) (134). 641 
Kong et al. suggested that these low rates may be due to regional distribution, as the 642 
majority of C. difficile colonized patients in this multi-institution study were based in 643 
hospitals with higher proportions of NAP1-associated CDI (133).  644 
 645 
A recent meta-analysis of studies reporting toxigenic C. difficile colonization rates upon 646 
hospital admissions, reported a rate of 8.1% among almost 9000 patients (135). Although 647 
this overall rate provides a strong insight into the prevalence of toxigenic C. difficile 648 
colonization, the meta-analysis excluded certain large studies due to methodology 649 
differences, in order to attain maximum compatibility of data sets. Such exclusions may well 650 
have impacted on the reported colonization rates.  651 
Two considerably smaller studies have reported higher C. difficile colonization rates, 652 
highlighting the potential for sampling bias. Hung et al. found that 20% of 441 patients 653 
admitted to a Taiwanese hospital were C. difficile positive, with two thirds carrying toxigenic 654 
C. difficile (11), whilst Alasmari and colleagues reported a rate of 21.2% (n=259), with almost 655 
75% harboring toxigenic strains (127). Prior healthcare exposure was very common and not 656 
statistically different between patients colonized with a toxigenic strain and non-colonized 657 
patients (prevalence of prior healthcare exposure 90% and 85%, respectively). However, 658 
Leekha and colleagues demonstrated recent health care exposure as a significant risk factor, 659 
when reporting a 9.7% toxigenic C. difficile colonization rate on admission (129). 660 
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 661 
Hospitalized patients 662 
Determination of hospital C. difficile colonization rates is helpful to understanding the 663 
potential for nosocomial transmission. Asymptomatic acquisition during hospital admission 664 
has generally been demonstrated to range between 3-21% (11, 12, 14, 71, 98, 131, 136, 665 
137). McFarland et al. were able to separate their study cohort into early (<2 weeks) and 666 
late (>2 weeks) acquisition relative to hospital admission (14). The majority of patients had 667 
early colonization, with a significant increase in disease severity associated with those 668 
subjects progressing to CDI after late acquisition. However, this understandably correlates 669 
with significant increases in other recognized CDI risk factors, including exposure to 670 
antibiotics and multiple comorbidities.  671 
 672 
Nevertheless, a study that involved mainly HIV positive (and younger) participants, 673 
demonstrated that all 44 C. difficile negative patients remained non-colonized throughout 674 
the period of hospitalization (138). This study population was largely accommodated in 675 
single rooms, which could have diminished the impact of positive carriers on transmission. 676 
In addition, Guerrero demonstrated that rectal and skin swabs from hospitalized, colonized 677 
patients yielded much lower counts than those from subjects with diarrhea, suggesting a 678 
reduced transmission potential associated with colonized individuals (8). Furthermore, 679 
Longtin and colleagues were able to show a significant decreasing trend in healthcare-680 
associated CDI cases after the implementation of contact isolation precautions for colonized 681 
patients identified upon admission (134). 682 
 683 
33 
 
Length of hospital stay not surprisingly is related to the risk of C. difficile colonization; a 684 
large study reported a 50% acquisition rate for those patients with a length of stay greater 685 
than 4 weeks. For those patients screened negative on admission, the average duration of 686 
hospital stay before a positive C. difficile culture, ranges between 12-71 days (11, 14, 137).  687 
 688 
Patients in long-term care facilities 689 
Previous reports of C. difficile colonization rates amongst residents of long-term healthcare 690 
facilities (LTHF) have ranged widely (4-51%) (139-142). A major caveat in the study reporting 691 
the highest colonization rate was that it was conducted during a CDI outbreak (143). 692 
Furthermore, two studies that found high rates examined relatively small cohorts (n=68 693 
(143) and n=32 (141)). Interestingly, the data from Riggs and colleagues showed 37% of 694 
colonized residents harbored the outbreak strain (RT027/NAP1) asymptomatically, whilst 695 
ZĞĂĂŶĚK ?^ƵůůŝǀĂŶĂůƐŽŝƐŽůĂƚĞĚĂƌĂŶŐĞŽĨŽƵƚďƌĞĂŬ-associated strains from the 696 
asymptomatic group, including RT027/NAP1, 078/NAP7, 018, 014/NAP4 and 026 (142). 697 
These rates must be considered with caution, as the presence of an epidemic strain in a 698 
given community is likely to inflate asymptomatic colonization rates. For example, the 699 
asymptomatic colonization rate before and post a CDI outbreak was reported to be 6.5% 700 
and 30.1%, respectively (p=0.01) (144). 701 
 702 
Arvand et al. identified colonization rates that ranged from 0-10% across 11 nursing homes 703 
in Germany and concluded that additional factors influenced the asymptomatic colonization 704 
prevalence, including antibiotic exposure rates, comorbidities of residents and the individual 705 
ĨĂĐŝůŝƚǇ ?ƐŝŶĨĞĐƚŝŽŶĐŽŶƚƌŽůƉƌŽĐĞĚƵƌĞƐ(140). Ryan et al. found similar distributions, likely 706 
reflecting differing resident morbidities and regional strain prevalence (139). Arvand and 707 
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colleagues found that nursing home residents were ten times more likely to be colonized 708 
with toxigenic strains than non-toxigenic types (140), similar to other reports (122, 139) 709 
demonstrating the presence of the toxin genes, tcdA and tcdB, in 70% of strains from the 710 
asymptomatic cohorts. Conversely, Rogers et al. found only toxigenic C. difficile in those 711 
with asymptomatic colonization (141). In one study where follow up samples from colonized 712 
residents (1-3 months after initial screening) were tested, 10/12 displayed persistent 713 
carriage by the same C. difficile PFGE type, possibly indicating a less transient nature 714 
amongst individuals in LTHFs (143). These data demonstrate the variability across studies, 715 
which likely reflect multiple confounders including stringency of infection control 716 
procedures, strain type, antibiotic use and comorbidities, and issues such as single room 717 
versus shared accommodation.  718 
 719 
Healthcare workers  720 
Asymptomatic gut colonization of healthcare workers (HCW) is a potential, but unproven 721 
source for C. difficile transmission. HCWs may well have a role in transmission, due to their 722 
frequent patient contact, but this could simply be due to transient hand contamination.  723 
Kato et al. carried out a large-scale study of Japanese groups including two cohorts of HCWs, 724 
and identified 4.2% of hospital employees as colonized by C. difficile (124). Van Nood et al. 725 
attempted to clarify whether intestinal colonization was related to the presence of spores 726 
ŽŶ,t ?ƐŚĂŶĚƐ ?KĨ ? ?ƵƚĐŚŚŽƐƉŝƚĂůǁŽƌŬĞƌƐ ? ?йĂŶĚ ? ?йǁĞƌĞC. difficile culture positive 727 
on hand print agar plates and fecal samples, respectively (145). Also, in demonstrating that 728 
colonization rates were similar across staff working on wards with and without CDI patients, 729 
they highlighted the potential for acquisition and/or transmission by means other than 730 
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,t ?ƐŚĂŶĚƐ ?hŶĨŽƌƚƵŶĂƚĞůǇ ?ŶŽƐƚƌĂŝŶƚǇƉŝŶŐǁĂƐĐĂƌƌŝĞĚŽƵƚŝŶ ŚŝƐƐƚƵĚǇĂŶĚƚŚĞƌĞĨŽƌĞ731 
definitive transmission relationships could not be determined.   732 
Several studies demonstrated low to non-existent intestinal colonization levels with 0-1% of 733 
healthcare workers being C. difficile positive (146-149). Friedman et al. did, however, point 734 
out the voluntary nature of study recruitment, and thus HCWs with poorer hand hygiene 735 
may have opted out, leading to a nonrepresentative cohort (147). Furthermore, these 736 
studies only sampled subjects once.  737 
Landelle et al. detected C. difficile spores on the hands of 24% of HCWs who were directly 738 
caring for CDI patients (150). Other studies have also shown that after caring for patients 739 
with CDI, the proportion of healthcare workers with hand contamination when gloves are 740 
not worn ranged from 8 to 59% (14, 151). This highlights the challenge in determining the 741 
ƌĞůĂƚŝǀĞŝŵƉŽƌƚĂŶĐĞŽĨƉĂƚŝĞŶƚƐ ?fecal C. difficile burden, versus HCW hand or environmental 742 
contamination as potential sources of transmission.  743 
 744 
Duration of carriage 745 
There is a paucity of research reporting duration of asymptomatic C. difficile carriage. Large-746 
scale, longitudinal studies are required to investigate length of carriage and the associated 747 
determinants. Nonetheless, some research does provide follow up data on asymptomatic 748 
hosts.  749 
 750 
Several studies have assessed duration of short term carriage (98, 152, 153). During weekly 751 
follow up of 32 asymptomatic subjects, Samore et al. found that 84% remained positive until 752 
discharge, although the mean duration of sampling was only 8.5 days (range 7-29 days) (98). 753 
Johnson et al. continued surveillance on 51 asymptomatic long-term hospital stay patients 754 
36 
 
for up to nine weeks, with no development of CDI during this time (152). Later, when 755 
investigating treatment efficacies for asymptomatic carriage, the same investigators
 
found 756 
that 60, 80 and 100% lost C. difficile colonization after 40, 70 and >90 days, respectively (in 757 
the absence of a targeted intervention) (153). Contemporaneous research demonstrated 758 
that only two of six healthy, colonized volunteers retained the same strain one month later 759 
(13). Although the data are limited, they indicate the short term, transient nature of 760 
symptomless C. difficile colonization, at least in the absence of repeated exposure to C. 761 
difficile risk factors such as antibiotics. Nonetheless, variation among patient cohorts and 762 
environments must be considered.  763 
Longitudinal studies of Japanese healthy populations have followed asymptomatic carriers 764 
among students, employees and hospital workers. Kato et al. performed a longitudinal 765 
surveillance on 38 asymptomatic carriers for 5-7 months and determined 12 (31.6%) 766 
remained C. difficile positive during this time (124). Half of these remained with the same 767 
PFGE type, whilst five had acquired a new strain. The remaining participant retained the 768 
original strain and acquired a new type. Therefore, only 18.4% of participants retained the 769 
same strain after six months, again implying a high rate of transient colonization. 770 
Nonetheless, analysis of a single, six-month follow up sample does not permit in-depth 771 
analysis of the dynamics of carriage and it remains unclear if carriage was lost after a few 772 
days, weeks or months. Testing of 18 asymptomatic subjects in three-month intervals, over 773 
one year period found that ten participants (55.6%) only tested positive for C. difficile on a 774 
single sampling occasion, indicating loss of carriage within three months; only three (16.7%) 775 
were persistently colonized throughout (123). This further supports the suggestion that 776 
intestinal colonization in healthy adults is largely a transient phenomenon. Of those testing 777 
positive on three or four instances, five harbored the same strain on consecutive sampling 778 
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occasions (3 students, 2 employees), potentially indicating an element of cross-transmission 779 
within cohorts sharing common physical areas, and even a possibility of a subject 780 
contaminating their own environment and reacquiring the strain later.  781 
 782 
A recent study of healthy subjects from Pittsburgh, USA provided analysis of participant 783 
demographics and dietary data in relation to the duration of C. difficile carriage (13). No 784 
correlations were found between previous CDI, prior antibiotics, healthcare exposure, race, 785 
ethnicity, consumption of uncooked meat or seafood and duration of carriage.  786 
 787 
Ribotype specific differences 788 
Determining the prevalence of ribotypes among asymptomatically colonized individuals may 789 
help to improve the understanding of potential sources of C. difficile, and specifically which 790 
toxigenic and common strain types originate from such individuals. Studies of colonizing 791 
strains have shown a broad distribution of PCR ribotypes, with reports of 37 ribotypes 792 
among 94 isolates (124) and 29 diverse sequence types from 112 carriers (115). Whilst it 793 
might be expected that there is a diverse strain distribution among asymptomatically 794 
colonized individuals, as with CDI patients, the prevalence of individual strain types is likely 795 
to vary depending on the virulence potential of a specific ribotype. Nonetheless, the 796 
relationship between ribotype prevalence in CDI patients and strain distribution among 797 
asymptomatic carriers remains unclear.  798 
 799 
In the context of outbreaks, colonization rates by hyper-virulent strains appear to be 800 
markedly increased. Loo et al. and Riggs et al. found very similar (asymptomatic) 801 
colonization rates for PCR ribotype 027/NAP1 strain (36.1% and 37%, respectively) (12, 143). 802 
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Contemporaneous research
 
highlighted the persistence of PCR ribotype 027/NAP1 in a New 803 
York, long-term care facility, where half of the asymptomatic population (19.3% of all 804 
residents) carried this strain (154). This is likely to be due to increased prevalence in the 805 
patient populations and consequent spore shedding in to the environment (155). 806 
Interestingly, three of the five asymptomatically colonized patients that developed 807 
subsequent CDI harbored the epidemic 027/NAP1 strain, hinting at its potential superiority 808 
in progression from colonization to symptomatic disease.  809 
 810 
Other ribotypes have also been implicated as dominant colonizing strains; earlier work 811 
reported that 51.7% of asymptomatically colonized, elderly patients were positive for 812 
ribotype 001/NAP2 on admission, with the remaining 48.3% consisting of 12 other ribotypes 813 
(156). As ribotype 001/NAP2 was deemed to predominate in Welsh hospitals at the time, 814 
this may be as expected. Other prevalent European ribotypes (157), including 012/NAPcr1, 815 
014/NAP4 and 020/NAP4 have also been reported as predominant strains among 816 
asymptomatic populations (127, 140). 817 
 818 
Conversely, in recent studies covering a period of marked reduction in PCR ribotype 819 
027/NAP1-associated CDI (157), asymptomatic colonization rates of this strain were 820 
considerably lower (140, 142). These data were supported by a large scale, UK transmission 821 
study (15), which also found no evidence of PCR ribotype 027/NAP1 colonization in UK 822 
hospitalized patients; no single strain predominated in this study. 
 
823 
 
824 
RISK FACTORS FOR C. DIFFICILE COLONIZATION 825 
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Clinical and epidemiological risk factors for CDI are well known, but risk factors for 826 
colonization with C. difficile have only come to attention recently. An important distinction 827 
has to be made between risk factors to be colonized in the community or at admission to a 828 
hospital, as opposed to risk factors for acquiring colonization during hospital admission.   829 
 830 
Risk factors for colonization in a community-setting 831 
Risk factors for being or becoming colonized in the community are not extensively studied. 832 
Clusters of colonized patients with identical C. difficile types have been identified within 833 
community settings (e.g. employees, students) and families, indicating cross-transmission 834 
from colonized individuals or acquisition from a common source (124). A study among 106 835 
healthy adults in Pennsylvania found no statistically significant differences in patient ?Ɛ 836 
characteristics or exposures between 7 colonized and 99 non-colonized subjects, but this 837 
may be due to the small sample size (13). Living in the proximity of livestock farms was not 838 
found to be a risk factor in a recent study among 2494 adults in the Netherlands (158). 839 
Antibiotic exposure in the 3 preceding months was however associated with a 3.7-fold 840 
increased risk of C. difficile colonization in the same study (158). A recent study among 338 841 
predominantly healthy infants (<= 2 years of age) showed that C. difficile colonization 842 
increased with pet dogs (159). 843 
 844 
Risk factors for colonization at admission  845 
Recognition of risk factors for being colonized at admission is important, as patients with 846 
these risk factors may introduce and spread C. difficile into the hospital. Epidemiological and 847 
clinical risk factors for (overall or toxigenic) colonization at the time of admission include 848 
recent hospitalization (15, 129, 133), chronic dialysis (129), corticosteroid/ 849 
40 
 
immunosuppressant use (15, 129, 133), gastric acid suppressant medication (15), and 850 
antibodies against Toxin B (133). (Table 2) The consistent association between previous 851 
healthcare contact and colonization by C. difficile likely means that hospitals remain 852 
important sources of C. difficile, related to host factors at time of admission (e.g. altered 853 
microbiota composition due to antibiotic use) and increased exposure to strains. However, 854 
patients colonized at admission may have acquired C. difficile from diverse sources. Notably, 855 
the healthcare associated C. difficile ribotype 027/NAP1 is less frequently found in carriers 856 
at admission, than in those who become colonized during admission (128, 133).  857 
 858 
Risk factors for acquiring C. difficile during hospital admission 859 
Previous hospitalization in the last 2 months, use of proton-pump inhibitors H2-blockers or 860 
chemotherapy (within the 8 weeks preceding the hospitalization or during hospitalization 861 
but before colonization was acquired) and cephalosporin use during admission were 862 
significant risk factors for becoming colonized (with toxigenic or non-toxigenic strains) 863 
during admission (12, 128). (Table 2) In one study, cefepime use and a toll-like receptor 4 864 
polymorphism were risk factors for acquiring toxigenic C. difficile colonization during 865 
admission (11). The presence of Toxin B antibodies was associated with asymptomatic 866 
colonization during admission (12). Interestingly, antibodies against Toxin B may have 867 
protective effect against the development of CDI. Likewise, compared to patients who 868 
acquired C. difficile and subsequently developed CDI, patients who acquired C. difficile 869 
colonization but remained asymptomatic had higher levels of IgG antibody against Toxin A 870 
at time of colonization (160). These observations may indicate that antibodies and/or 871 
acquired immunity (e.g. due to previous hospitalizations) might confer resistance to the 872 
development of symptomatic CDI (see before). Patients who acquired C. difficile and 873 
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developed asymptomatic colonization were less frequently colonized with the hypervirulent 874 
ribotype 027/NAP1 strain compared to those who developed CDI (12, 128, 160). This 875 
suggests that the virulence of the acquired strain can influence the development of 876 
colonization or infection.  877 
 878 
Risk factors for colonization by toxigenic versus non-toxigenic strains 879 
A recent study showed that hospitalized patients colonized by toxigenic strains and non-880 
toxigenic strains do not share risk factors. Risk factors for colonization by a toxigenic strain 881 
included a higher number of admissions in the previous year, antimicrobial exposure during 882 
the current admission and the presence of gastro-esophageal reflux disease. Risk factors for 883 
colonization by a non-toxigenic strain were chronic kidney failure and chronic obstructive 884 
pulmonary disease. Unfortunately, the design of this study was cross-sectional and 885 
therefore the time period of C. difficile acquisition (i.e. before at admission or during 886 
admission) could not be established in these patients (161). Another study tried to 887 
determine if the type of antibiotics used during admission impacts the risk for acquisition of 888 
either toxigenic or non-toxigenic C. difficile. They found that the use of cephalosporins was a 889 
risk factor for both conditions: acquisition of a toxigenic strain was associated with the use 890 
of cefepime, while the acquisition of a non-toxigenic strain was associated with the use of 891 
cefuroxime. Moreover, the use of glycopeptides was a risk factor for acquiring a non-892 
toxigenic strain during admission (11). For patients colonized on admission, associations 893 
between classes of antibiotics used and the colonization of either toxigenic or non-toxigenic 894 
C. difficile have also been reported, but multivariate analyses to identify independent risk 895 
factors have not yet been performed (127). 896 
 897 
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C. DIFFICILE COLONIZATION AND SUBSEQUENT CDI 898 
One of the major questions is, do C. difficile colonized individuals have an increased risk of 899 
developing subsequent CDI, or are they protected against disease? A lower risk for C. 900 
difficile colonized patients of subsequently developing CDI was found in a frequently cited 901 
but older meta-analysis of four studies (162). The major drawback of this review, however, 902 
is that patients colonized by toxigenic or non-toxigenic strains were not analyzed separately; 903 
this difference may be of importance as 44% of colonized patients in this meta-analysis 904 
harbored a non-toxigenic strain. Also, all four studies were performed pre-1994, before the 905 
emergence of hypervirulent strains and recognition of community-associated CDI. 906 
Furthermore, colonization was determined at different time points: at admission (71, 98), at 907 
start of tube feeding with patients colonized at admission excluded (163) or after a hospital 908 
stay of at least 7 days (152). Colonized patients therefore included some patients that 909 
acquired colonization during admission. The risk that these latter patients go on to develop 910 
CDI during the hospital stay may be different from that for individuals already colonized at 911 
admission. A recent meta-analysis aimed to include studies in which patients were colonized 912 
at admission with toxigenic strains only (11, 15, 98, 127, 131, 135, 164-166). However, not 913 
all included studies succeeded in obtaining samples within 48hrs or 72hrs of admission (15, 914 
98). Also, a study that included patients at admission to a rehabilitation unit (after an 915 
average stay of 30 days in acute care) was included (166). In one study, the distinction 916 
between colonization of a toxigenic strain and CDI was difficult to establish, as all patients 917 
received a hematopoietic stem cell transplantation and donor lymphocyte infusion; almost 918 
all such patients subsequently develop diarrhea. In patients known to carry a toxigenic C. 919 
difficile strain, diarrhea may have been falsely attributed to CDI (164). Notwithstanding 920 
these limitations, all studies pointed to an increased risk for patients colonized with 921 
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toxigenic C. difficile at admission to progress to CDI: overall, the relative risk was 5.86 (95% 922 
CI 4.21-8.16). (Table 3) Some recent studies were not included in this meta-analysis. A 923 
recent large study, which screened n=3605 of 4508 hospital admissions, found that patients 924 
carrying toxigenic strains on admission were at a much increased risk of developing CDI (CDI 925 
rates 9.4% vs 2.3% for non-toxigenic C. difficile carriers) (70). The risk of CDI in non-926 
colonized patients who were exposed to subjects colonized by a toxigenic strain was also 927 
significantly increased (4.6% vs 2.6% for non-exposed patients; odds ratio for CDI if exposed 928 
to carrier, 1.79; 95% CI, 1.16 W2.76). However, this study appeared to diagnose CDI based on 929 
the presence of toxigenic C. difficile strains rather than toxin, and so the case incidence is 930 
likely to have been overestimated. In turn, the association between colonization by, or 931 
exposure to, toxigenic strains and subsequent CDI may have been exaggerated (70). A much 932 
smaller study did not report any CDI cases among 37 patients colonized on admission (128) 933 
(Table 3). 934 
Two other recent studies describe the risk of colonized ICU patients to develop CDI. The 935 
study by Tschudin-Sutter et al. in a cohort of 542 ICU patients described a relative risk to 936 
develop CDI of 8.6 for patients colonized on admission and a relative risk of 10.9 for patients 937 
who became colonized during hospitalization (132). Zhang and colleagues however, 938 
identified 6 patients who were colonized on admission to the ICU, but none of them 939 
developed CDI. During their study period 4 patients developed CDI, but all were not 940 
colonized on admission to the ICU (167). These conflicting results are probably caused by 941 
small samples sizes, a relatively rare outcome event (3 vs 0 colonized patients progressed to 942 
CDI) and different predominant strains.  943 
 944 
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From the above we can conclude that patients asymptomatically colonized by toxigenic 945 
strains may progress to CDI during admission. However, for patients asymptomatically 946 
colonized by non-toxigenic strains there seems to be no increased risk of progressing to CDI 947 
and these patients may even be protected from developing CDI.  948 
 949 
INFECTION CONTROL AND ANTIMICROBIAL STEWARDSHIP IMPLICATIONS FOR 950 
ASYMPTOMATIC CARRIERS 951 
Symptomatic CDI patients are believed to be the main source of nosocomial transmission, 952 
and current guidelines recommend their systematic detection and isolation (5). Due to a 953 
paucity of data at the time of writing of this review, the isolation of asymptomatic carriers is 954 
not recommended. Whether these carriers should be isolated remains an important clinical 955 
question stemming from the growing body of literature on the subject. Mathematical 956 
modeling of C. difficile transmission and simulation of screening and isolation of carriers has 957 
shown the intervention to be effective at reducing CDI rates (168, 169). However, a clinically 958 
based study to directly answer this question has not been conducted until recently (134). 959 
 960 
Longtin et al. explored the effect of isolating asymptomatic C. difficile carriers on the 961 
incidence of hospital acquired CDI in an acute care hospital in Quebec, with high baseline 962 
rates of CDI (134). A quasi-experimental design was employed, using change in CDI 963 
incidence in other Quebec hospitals as controls. The effect of the intervention (isolation of 964 
carriers) was evaluated through a time series analysis. Compared with the pre-intervention 965 
period, the incidence of CDI decreased significantly after the intervention. In addition, the 966 
effect was confirmed using two methods of analysis, segmented regression analysis and 967 
autoregressive integrated moving average (ARIMA) modeling, indicative of the robustness of 968
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the results. Incidence rates of CDI in the study hospital remained low a year after the study 969 
terminated, demonstrating the sustained effect of this intervention. 970 
This study provides the most convincing evidence to date for the significant effect of 971 
isolating carriers. The authors assessed confounding elements; such as intensity of CDI 972 
testing, total antimicrobial use and proton pump inhibitor use, which remained stable 973 
during the study period. Concurrently, a significant decrease in the use of metronidazole 974 
and oral vancomycin suggested true clinical impact from the observed decrease in incidence 975 
and trend. Compliance with hand hygiene increased, but utilized alcohol-based solution not 976 
effective against C. difficile spores. Some potential confounders that were not assessed 977 
include compliance with isolation precautions, environmental cleaning, improvement in 978 
appropriate antibiotic use, and knowledge of C. difficile carrier status on the management of 979 
a patient (170). 980 
 981 
Ultimately, these promising findings need to be reproduced in a multicenter, cluster 982 
randomized trial, prior to being considered for widespread implementation. If these results 983 
are confirmed in various different hospital settings, adoption of screening and isolation of 984 
asymptomatic carriers may be an important strategy to decrease CDI rates. However, this 985 
will raise several practical questions, such as whether universal versus targeted screening 986 
should be adopted and what the optimal screening method is. Given known risk factors for 987 
colonization on admission, a reasonable approach may be to selectively target high-risk 988 
patients and isolate them on admission to hospital (133). Other issues that would need to 989 
be addressed include frequency of screening during hospitalization, the optimal isolation 990 
protocol, the impact on patient perception of care and the additional workload burden on 991 
frontline healthcare workers and the microbiology laboratory. 992 
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Reducing inappropriate antimicrobial use through antimicrobial stewardship programs 993 
(ASPs) has been shown to decrease rates of CDI (171-173), but given the lack of widespread 994 
screening for asymptomatic carriers, ASPs targeted at this population have not been 995 
studied. It does not necessarily follow that targeting colonized patients, as a whole group, 996 
would decrease CDI rates, as some of these patients may be long-time colonized patients 997 
with immunity and decreased risk of developing symptomatic CDI. These patients are likely 998 
different from patients who may still be colonized with C. difficile after an episode of 999 
symptomatic CDI (10, 68). One study showed a three-fold increase in recurrence of CDI in 1000 
patients exposed to antimicrobials after resolved CDI, compared with those who were not 1001 
exposed (174). Therefore, patients with prior CDI, an easily identifiable subset of 1002 
asymptomatic carriers, probably represent colonized patients at highest risk of developing 1003 
infection, and may represent suitable targets for focused stewardship efforts. 1004 
 1005 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 1006 
The intriguing concept of C. difficile colonization has garnered much attention during the 1007 
last decade. Gut microbiota studies and immunologic studies have provided some insight in 1008 
the conditions that allow for colonization and protect against disease progression. However, 1009 
more studies are needed to assess the precise role of changes in microbiota and the precise 1010 
triggers of spore germination and colonization, as well as changes and initiators that lead to 1011 
toxin production. It also needs to be explored why some ŝŶĚŝǀŝĚƵĂůƐ ? transition to C. difficile 1012 
carrier status and what interventions could terminate colonization or could block the 1013 
progression to CDI. 1014 
The realization that C. difficile colonized patients may be the most important unexplained 1015 
reservoir for C. difficile transmission has led to epidemiological studies investigating 1016 
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colonization rates among different populations and risk factors for this condition. Colonized 1017 
patients on admission appear to play an important role in introducing and maintaining 1018 
transmission in the ward and hence, risk factors for colonization on admission are of specific 1019 
interest. To further study the acquisition and transmission of C. difficile, all patients 1020 
admitted to the hospital should be screened for colonization by (and preferably sustained 1021 
carriage of) C. difficile. C. difficile positive individuals should be questioned about risk factors 1022 
for acquisition and should be followed during admission for the development of 1023 
symptomatic CDI. Epidemiological investigations and molecular typing methods should be 1024 
applied to examine possible linkage of C. difficile colonized individuals to CDI cases. In this 1025 
way, risk factors for C. difficile colonization can be identified and the role of C. difficile 1026 
positive individuals in transmission of the disease can be elucidated. It would be interesting 1027 
to determine if there are host and pathogen factors that affect transmissibility of C. difficile. 1028 
More evidence from different settings is needed to determine whether specific control 1029 
measures targeting colonized patients may be justified to prevent spread. In addition, the 1030 
protective effects of C. difficile vaccines are being examined, but information on the 1031 
consequences of colonization and spread to non-vaccinated individuals would be relevant.        1032 
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Figure 1. C. difficile colonization versus C. difficile infection. CDI - Clostridium difficile 
infection. 
 
 
Figure 2. Prevalence of colonization among community-dwelling adults, patients at 
hospital admission to the hospital and LTCF residents. Hollow circles represent CDC 
prevalences, solid circles represent tCDC prevalences. Size of the circles represents samples 
size. The different colors represent the different studies (see legend). CDC - C. difficile 
colonization (including non-toxigenic and toxigenic strains), tCDC - toxigenic C. difficile 
colonization, LTCF - long term care facility. 
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Table 1।Diagnostic methodologies detecting C. difficile or its toxins. tCD  W toxigenic C. difficile, ntCD  W nontoxigenic C. difficile, GDH  W 
glutamate dehydrogenase, EIA  W enzyme immunoassay, CCNA  W cell cytotoxicity neutralization assay, CDI  W Clostridium difficile Infection, PCR  W 
polymerase chain reaction. 
 
 
 
 
 
 
 
 
 
 
Diagnostic 
Test 
Target of detection 
Able to detect 
colonization? 
Remarks 
Direct 
culture 
C. difficile Yes Does not differentiate between colonization or infection by CD, does not 
differentiate between tCD and ntCD 
Enrichment 
culture 
C. difficile Yes Does not differentiate between colonization or infection by CD, does not 
differentiate between tCD and ntCD, thought to be more sensitive than 
direct culture when low numbers of vegetative cells or spores are present 
GDH EIA GDH Yes Does not differentiate between colonization or infection by CD, does not 
differentiate between tCD and ntCD 
Toxigenic 
culture 
Toxigenic C. difficile Yes Does not differentiate between infection and colonization by tCD 
PCR of toxin 
genes 
tcdA, tcdB, binary 
toxin genes 
Yes Does not differentiate between infection and colonization by tCD 
Toxin A/B 
EIA 
Toxins A and B No Detects Toxins A and B and not the presence of the organism, therefore 
cannot be utilized to identify asymptomatic colonization 
CCNA Toxin B No Detects Toxin B and not the presence of the organism, therefore cannot 
be utilized to identify asymptomatic colonization 
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Table 2. Studies investigating risk factors for C.difficile colonization on admission or 
acquisition of C. difficile acquisition during admission. Studies were included if: publication 
since 1994, investigating either risk factors for colonization at admission or risk factors for 
colonization acquisition during admission (studies investigating risk factors for being 
colonized at a certain time point during hospitalization were excluded), sample size > 100, 
risk factors assessed by multivariate regression. CDC -Clostridium difficile colonization, tCDC- 
toxigenic Clostridium difficile colonization. 
Condition Identified risk factor Reference 
Risk factors for colonization at admission 
CDC previous hospitalization 133, 15 
  previous CDI episode 133 
  previous use of corticosteroids or other immunosuppressant medication 133, 15 
  presence of antibodies against Toxin B 133 
  current loose stools/diarrhea but not meeting CDI criteria   15 
tCDC previous hospitalization 129 
  chronic dialysis 129 
  use of corticosteroids 129 
Risk factors for acquiring colonization during admission 
CDC previous hospitalization 12 
  use of chemotherapy  12 
  use of PPI or H2-blockers 12 
  presence of antibodies against Toxin B 12 
tCDC TLR4 polymorphism 11 
  cefepime use during admission 11 
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Table 3. Studies investigating the risk of development of CDI among patients with 
toxigenic C. difficile colonization on admission. Studies were included if: published since 
1994, sample size > 100 patients, comparison of patients with toxigenic C. difficile 
colonization on admission with controls (patients with non-toxigenic C. difficile colonization 
and non-colonized patients together). Relative risks were calculated as the risk for tCDC 
patients compared to the risk for non-colonized and ntCDC patients together and were 
unadjusted. RR - relative risk, HSCT - hematopoietic stem cell transplantation, tCDC - 
toxigenic Clostridium difficile colonization, ntCDC - non-toxigenic Clostridium difficile 
colonization, CDI - Clostridium difficile infection, LOS - length of stay, ICU - intensive care 
unit, na - not available. 
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Study 
Country and 
period 
Setting and 
patients 
Follow up 
period 
Included 
patients (N) 
Preva-
lence 
tCDC  
(%) 
CDI 
among 
tCDC  
(%) 
CDI 
among 
controls 
(%) 
RR for 
CDI   
(95% CI) Remarks 
Samore     
(ref 98) 
US             
1991 
patients with an 
anticipated LOS 
of at least 5 days 
admitted or 
transferred to 
general medical 
and surgical 
wards and ICUs 
until 
discharge 
496 24/496 
(4.8) 
1/24         
(4.2) 
8/472    
(1.7) 
2.46              
(0.32-
18.87) 
90 of 496 samples 
(18.1%) were not 
obtained within 72hrs 
of admission 
Soyletir     
(ref 131) 
Turkey 
published 
1996 
patients 
admitted to a 
general medical 
ward with a LOS 
of at least 48hrs 
until 
discharge 
202 0/202      
(0) 
0/0                    
(0) 
0/202            
(0) 
na none of the patients 
was colonized at 
admission 
Gupta        
(ref 165) 
US and 
Canada 
2009-2011 
patients >60yrs 
admitted to 
general medical 
and surgical 
units, on 
antibiotics 
until 30 days 
after 
discharge or 
60 days in 
hospital 
(whichever 
came first) 
1099 91/1099 
(8.3) 
9/91         
(9.9) 
11/1008 
(1.1) 
9.06 
(3.86-
21.30) 
asymptomatic 
carriage was 
diagnosed by culture 
and REA typing but 
could have included 
both tCDC and ntDCD 
Alasmari    
(ref 127) 
US            
2010-2011 
adult patients 
with an 
anticipated LOS 
>48hrs admitted 
until 60 days 
after 
discharge 
259 40/259 
(15.4) 
1/40         
(2.5) 
2/219    
(0.9) 
2.74              
(0.25-
29.48) 
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to general 
medical and 
surgical wards 
Dubberke 
(ref 128) 
US            
2010-2012 
adult patients 
admitted to 
medical or 
surgical wards 
with an 
anticipated LOS 
>48hrs 
until 60 days 
after 
discharge 
235 37/235 
(15.7) 
0/37         
(0) 
2/198    
(1.0) 
na partly same patient 
cohort as Alasmari 
Bruminhent 
(ref 164) 
US             
2011-2012 
patients 
admitted to a 
bone marrow 
transplant unit 
for an HSCT 
until 100 days 
after HSCT 
150 16/150 
(10.7) 
14/16           
(87.5) 
23/134 
(17.2) 
5.10              
(3.36-
7.72) 
distinction between 
CDI and colonization 
by toxigenic strains 
difficult to establish as 
almost all patients 
develop diarrhea after 
HSCT and CDI testing 
did not include free 
toxin detection in all 
cases 
Hung          
(ref 11) 
Taiwan    
2011-2012 
adult patients 
with an 
anticipated LOS 
of at least 5 days 
admitted to a 
general medical 
ward 
until 
discharge 
from last 
hospitalizatio
n 
441 58/441 
(13.2) 
8/58         
(13.8) 
6/383    
(1.6) 
8.80              
(3.17-
24.46) 
 
Blixt           
(ref 70) 
Denmark 
2012-2013 
patients 
admitted to 
medical 
one month (in 
and outside 
hospitals) 
3464 213/346
4 (6.1) 
20/213         
(9.4) 
76/3251 
(2.3) 
4.02 
(2.50-
6.44) 
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departments at 2 
university 
hospitals 
Tschudin-
Sutter (ref 
132) 
US             
2013 
patients 
admitted to an 
ICU within 48hrs 
of hospital 
admission 
until 
discharge 
542 17/542 
(3.1) 
2/17         
(11.8) 
6/525    
(1.1) 
10.29            
(2.24-
47.3) 
  


